

Ifw

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on the date shown below:

INFORMATION DISCLOSURE
STATEMENT

Patent Application
Docket No. GJE-7489
Serial No. 10/575,913

November 13, 2006

David Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : *Not yet assigned*
Applicant(s) : John Brew *et al.*
Serial No. : 10/575,913
Filed : April 13, 2006
For : The Use of Non-Opiates for the Potentation of Opiates

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

The above-identified patent application was filed in the U.S. Patent Office as a national application under 35 USC §371.

For the examiner's convenience, the applicants are attaching a copy of the International Search Report as well as copies of the documents cited in the International Search Report. Also attached is Form PTO/SB/08 listing the references. Applicants have not submitted copies of the U.S. patents or published U.S. Patent Applications cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

In accordance with 37 CFR §1.56, the applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

DRS/wrc

Attachments: Form PTO/SB/08 (2 pages)
International Search Report
Copies of references cited



PTO/SB/08A (07-05)
Approved for use through 07/31/2006.

Substitute for form 1449 PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/575,913
Filing Date	April 13, 2006
First Named Inventor	John Brew
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	GJE-7489

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-5,543,434 A1	08-06-1996	Stuart L. Weg	All
	U2	US-6,538,008 B1	03-25-2003	Susan Boyce	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	JP 11 029 476	02-02-1999	Grelan Pharmaceut. Co. Ltd.	Abstract	
	F2	WO 99/13799 A1	03-25-1999	Euro-Celtique, S.A.	All	
	F3	WO 99/18967 A1	04-22-1999	Panos Therapeutics Ltd.	All	
	F4	WO 03/072057 A2	09-04-2003	Univ. of TX Systems, Board of Regents	All	
	F5	WO 03/092689 A1	11-13-2003	Arakis LTD.	All	
	F6					

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/575,913
Filing Date	April 13, 2006
First Named Inventor	John Brew
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	GJE-7489

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BERNARDI, MARA; ALFIO BERTOLINI; KRISTYNA SZCZAWINSKA; SUSANNA GENEDANI (1996) "Blockade of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine, in mice" <i>European Journal of Pharmacology</i> 298:51-55, (Elsevier, publisher).	
	R2	KOZELA, E. and P. POPIK, Published on line August 9, 2002, © Springer-Verlag, "The effects of NMDA receptor antagonists on acute morphine antinociception in mice" <i>Amino Acids</i> 23:163-168, printed in Australia.	
	R3	REDWINE <i>et al.</i> , "Effects of NMDA receptor antagonists on acute μ -opioid analgesia in the rat," <i>Pharmacology, Biochemistry and Behavior</i> , 2003, pp. 361-372, Vol. 76.	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.